Comparison of Sugammadex and Sugammadex-neostigmine Combination in the Antagonism of Moderate Neuromuscular Block

Comparison of Sugammadex and Sugammadex-neostigmine Combination in the Antagonism of Moderate Neuromuscular Block Induced by Rocuronium: A Prospective Randomized Cotrolled Study

In this prospective randomized controlled study the investigators compare the sugammadex-neostigmine combination and single dose sugammadex in terms of side effects and cost for the antagonism of moderate neuromuscular block induced by rocuronium.

Sugammadex is a novel drug used to reverse neuromuscular blockade. It shows its effect by binding with steroid neuromuscular agents at a ratio of 1:1. Compared to anticholinesterase and other neuromuscular reverse agents, sugammadex shows less cholinergic side effects and less residual muscle relaxation. Besides all these, sugammadex reverses neuromuscular blockade very quickly. In addition to these benefits, it has side effects such as hypersensitivity and this side effect can be seen more at high doses. In addition, sugammadex is more costly than other neuromuscular reverse agents.

In this prospective randomized controlled study the investigators compare the sugammadex-neostigmine combination and single dose sugammadex in terms of side effects and cost for the antagonism of moderate neuromuscular block induced by rocuronium.

Inclusion Criteria:

• elective general anesthesia
• Female gender
• Between the ages of 18-65

Exclusion Criteria:

• ASA ≥ 3
• Pregnancy
• Contraindication to use of anesthetic drugs
• Kidney failure
• Liver failure
• Heart failure
• BMI <18 and BMI > 35 kg/m2
• anticipated difficult airway
• neuromuscular disease
• Use of drugs that impair neuromuscular transmission
• Patients who develop unexpected massive hemorrhage
• Those who do not have the ability to read, understand and sign the consent form
• Refusal of patient